Related Experiment Videos
Prognostic impact of coexisting lung disease in patients with pulmonary arterial hypertension
Taku Komori1, Takahiro Sato2, Shuhei Yoshikawa1
1Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Background:
Pulmonary arterial hypertension (PAH) is a progressive disorder of the pulmonary vasculature. A subset of patients with PAH exhibit concomitant lung disease (LD); nonetheless, the clinical significance of this overlap remains uncertain.
Methods:
We retrospectively compared patients diagnosed with PAH and those with group 3 pulmonary hypertension (G3PH). Baseline chest computed tomography scans were reviewed, and the patients with PAH were stratified into two subgroups: without LD (PAH-no LD) and with LD (PAH-LD). Clinical characteristics and outcomes were compared among the three groups.
Results:
Overall, 158 patients were included (37 PAH-no LD, 39 PAH-LD, and 82 G3PH). Compared with the PAH-no LD group, patients with PAH-LD were older, had worse functional capacity, and demonstrated shorter 6-min walk distances, similar to those in the G3PH group. The 1-, 3-, and 5-year survival rates of patients with PAH-LD were lower than those of individuals with PAH-no LD, but comparable to those of patients with G3PH. In multivariable Cox regression analysis restricted to patients with PAH, concomitant LD was associated with increased mortality after adjustment for age (age-adjusted hazard ratio, 4.80; 95% confidence interval, 1.15-19.99). Respiratory failure accounted for approximately 40% of deaths in the PAH-LD and G3PH groups, but not in the PAH-no LD group.
Conclusions:
In this cohort, nearly half of the patients with PAH had coexisting LD, which was associated with impaired exercise capacity and poor prognosis, comparable to that of G3PH. Therefore, early identification and tailored management of this high-risk PAH phenotype is necessary.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...